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Aims: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated
in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease.
With this fixed dosing regimen, only approximately 40% of patients reach adequate
plasma levels within the therapeutic index. Therapeutic drug monitoring (TDM) is a
solution to reach plasma levels within the therapeutic index. However, introducing
TDM will also increase costs, due to prolonged imatinib use and laboratory costs.
The aim of this study was to evaluate the cost‐effectiveness of TDM in patients with
metastatic/unresectable GIST treated with imatinib as a first line treatment,
compared with fixed dosing.
Methods: A survival model was created to simulate progression, mortality and
treatment costs over a 5‐year time horizon, comparing fixed dosing vs TDM‐guided
dosing. The outcomes measured were treatments costs, life‐years and quality‐
adjusted life‐years.
Results: Total costs over the 5‐year time horizon were estimated to be €106 994.85
and €150 477.08 for fixed dosing vs TDM‐guided dosing, respectively. A quality‐
adjusted life year gain of 0.74 (95% confidence interval 0.66–0.90) was estimated with
TDM‐guided dosing compared to fixed dosing. An average incremental cost‐
effectiveness ratio of €58 785.70 per quality‐adjusted life year gained was found,
mainly caused by longer use and higher dosages of imatinib.
Conclusion: Based on the currently available data, this analysis suggests that TDM‐
guided dosing may be a cost‐effective intervention for patients with metastatic/
unresectable GIST treated with imatinib which will be improved when imatinib losses
its patency.
KEYWORDS
cost‐effectiveness, fixed dosing, gastrointestinal stromal tumours, imatinib, therapeutic drug
monitoring
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1 | INTRODUCTION
Gastrointestinal stromal tumours (GIST) are the most common type
of soft tissue sarcoma. Worldwide, the annual incidence of GIST is
about 10 cases per million people, corresponding to at least 8000
new cases per year in Europe.1,2 Patients with metastatic or
unresectable GIST receive fixed dosed imatinib as first‐line treatment
until progressive disease.3,4 When disease progression is noticed, the
dose of imatinib is doubled, followed by second‐line treatment with
sunitinib and third‐line treatment with regorafenib after each
progression. Sunitinib, regorafenib and double‐dosed imatinib are
regarded as more toxic with worse quality of life compared to
standard dosed imatinib. In its palliative intent, the goal of
treatment with imatinib, sunitinib and regorafenib in patients with
GIST is to improve the progression free survival, with the lowest
toxicity.5-7
Imatinib mesylate is an oral tyrosine kinase inhibitor that has
been approved at fixed doses of once daily 400 mg for use in
different types of cancer, e.g. BRC‐Abl positive chronic myeloid
leukaemia and GIST.8,9 However, since this drug shows large
interpatient variability in pharmacokinetics sub‐ and supratherapeutic
exposures may be encountered which could affect treatment out-
come. In addition, in retrospective analyses improved efficacy was
shown at plasma concentrations >1100 μg/L while more adverse
events were observed at plasma concentrations >3200 μg/L.10,11
Therefore, it is important to treat patients within the therapeutic
index. Since many factors may influence the plasma exposure of
imatinib, it is not possible to predict whether an individual patient
will reach an adequate plasma exposure using a standard fixed dose
of the drug.
Therapeutic drug monitoring (TDM) is a technique used to deter-
mine plasma exposure for certain drugs, and to adjust the dose in
order to achieve plasma exposure within the therapeutic index. A
study by Lankheet et al12 shows that the use of TDM in GIST patients
treated with imatinib results in 95% of the patients to achieve
adequate therapeutic plasma concentrations. Additionally, TDM has
been shown to improve safety and efficacy of many targeted oral
anticancer drugs.13,14 A relationship between plasma exposure and
treatment outcome has been retrospectively established for imatinib
in patients with GIST,10 supporting the rationale for the use of TDM
in GIST patients treated with imatinib. While the effect of TDM to
redistribute patients to adequate plasma concentrations has been
proven, it is currently unknown what the financial consequences of
TDM is compared with fixed dosing. While an increase in clinical
efficacy may result in a reduction in costs associated with slower
disease progression and less adverse events, it is unclear whether
these savings weigh up to the additional costs that come with the
use of increased and prolonged dosages and laboratory handling costs
associated with TDM.
The aim of this study is to evaluate the cost‐effectiveness of TDM
in patients with metastatic/unresectable GIST treated with imatinib as
first line treatment, compared with fixed dosing of imatinib.
2 | METHODS
2.1 | General considerations
To determine the possible gain of TDM over fixed dosing in GIST
patients treated with imatinib, the costs and effects of both groups,
from a societal perspective, were modelled over 5 years. The main
comparison made in this model is the effect of TDM during the initial
imatinib treatment on costs, life‐year and quality‐adjusted life‐year
(QALY) gains, compared with fixed dosing. The difference TDM intro-
duces in the treatment of metastatic GIST patients is fully located in
the imatinib treatment health‐state, and allows for patients receiving
a sub‐ or supratherapeutic dose of imatinib to be redistributed in the
correct therapeutic index within the imatinib health‐state. This results
in higher drug costs but prolonged time to progression when trans-
ferred from subtherapeutic to therapeutic and lower drug costs and
a lower chance of side effects when transferred from supratherapeutic
to therapeutic.
2.2 | Model structure
A partitioned survival model was created using Microsoft Excel. This
analysis included a fictitious cohort of 10 000 patients with metastatic
and/or unresectable GIST, starting the first line of treatment with
imatinib. The model consisted of 6 mutually exclusive health‐states:
regular dose imatinib progression‐free (IPF); escalated dose imatinib
progression‐free (EIPF); sunitinib progression‐free; regorafenib
progression‐free; best supportive care (BSC); and death (Figure 1).
The regular dose IPF health‐state was subdivided into subtherapeutic,
therapeutic and supratherapeutic imatinib plasma concentrations, to
allow optimization with TDM and decrease of imatinib plasma levels
in the first treatment period15 to be noticeable in this health‐state,
and its effect on subsequent health‐states. All patients entered the
model in the IPF health‐state. Progression‐free survival (PFS) and
What is already known about this subject
• Patients suffering from gastrointestinal stromal tumours
(GIST) treated with fixed dose imatinib as a first‐line
treatment, may receive suboptimal dosing and thereby
suboptimal treatment outcomes. Therapeutic drug moni-
toring (TDM) has proven to be a simple and effective
measure to increase the number of patients with drug
levels within the therapeutic window.
What this study adds
• This paper explores the effect of TDM on quality of life
gains, occurrences of adverse events, and associated
costs in GIST patients treated with imatinib.
• TDM may be a cost‐effective intervention for GIST
patients treated with imatinib.
ZUIDEMA ET AL. 1995
overall survival (OS) curves for each treatment health‐state were used
to determine the time‐dependent transition probabilities between
health‐states. The model uses 14‐day cycles, based on the first
moment TDM takes place after starting the IPF line of treatment.
The different lines of treatments used in this model (IPF, EIPF, suniti-
nib progression‐free, regorafenib progression‐free and BSC) are in line
with the clinical guidelines formulated by the European Society for
Medical Oncology.16 Reduction of imatinib exposure of ~30% over
the first 3 months is taken into account for the imatinib groups only,
to further analyse the effect of TDM.15 Perfect adherence to the
guidelines is assumed for each fictitious patient. The time horizon
for this model is 5 years, based on available data for survival for the
IPF treatment.10 Health outcomes were measured in life‐years and
QALYs. Monetary values were measured and if needed converted into
euros.
2.3 | Model data
2.3.1 | Clinical data
Data for the distribution of patients in the IPF group over the thera-
peutic subgroups, and the effect of TDM, defined as the percentage
of patients being redistributed of the therapeutic subgroups, was
gathered from an study from Lankheet et al.12 This study was a retro-
spective cohort study in patients treated with imatinib in whom TDM
was performed from August 2012 to April 2016. The intrapatient
variability in imatinib PK was not taken into account since Abrantes
et al demonstrated that for the best result one should exclude the por-
tion of unexplained variability related to interoccasion variability in the
individual parameters to calculate the future dose.17
2.3.2 | Model data inputs
A complete list of all input parameters can be found in supplementary
file 1. Progression probabilities from 1 line of treatment to the next
were based on Kaplan–Meier PFS data gathered for each health‐state.
This data was converted into time‐dependent probabilities for
progression from 1 line of treatment to the next for each cycle in the
model, to reflect reality as accurately as possible. Due to deaths being
counted as progression in all found survival data, chances of death for
each treatment group was determined by dividing the OS data by the
PFS data, for each specific cycle, yielding the patients who died during
treatment and excluding them from entering the next line of treatment.
Transition probabilities from IPF to EIPF were different for each
therapeutic subgroup, based on the data from Demetri et al10 to
account for differences in progression due to the effect of the respec-
tive therapeutic groups. PFS for the supratherapeutic health‐state was
extrapolated beyond 42 months due to lack of data. OS data for the
subtherapeutic imatinib health‐state was not available, and was
extrapolated based on the PFS data for this health‐state. The further
treatment groups of sunitinib and regorafenib were not split in thera-
peutic subgroups due to lack of data. Chances of adverse events
occurring were determined for each treatment group. For each treat-
ment group the most common adverse events have been used. Only
severe (grade 3 or 4) adverse events have been taken into account
in this model, since the costs of grade 1 and 2 adverse events are
considered to be low.
2.3.3 | Costs
Direct drug acquisition costs were gathered from the Dutch National
Health Care Institute (www.medicijnkosten.nl, accessed October
FIGURE 1 (A) Flowchart of metastatic
gastrointestinal stromal tumour progression
treated with fixed dosing imatinib.
(B) Flowchart of metastatic gastrointestinal
stromal tumour progression treated with
therapeutic drug monitoring‐adjusted imatinib
dosing. Arrows indicated by 1 represent the
reduction of blood plasma concentration
caused by lower bioavailability for imatinib
over time. Arrows indicated by 2 represent
the effect of therapeutic drug monitoring
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2017), and based on the drug dose as described in the clinical guide-
lines for treatment of metastatic and unresectable GIST. Diagnostic
and follow‐up procedures in line with the clinical guidelines were also
implemented in the model. Prices of these procedures were gathered
using the Dutch Healthcare Authority. The price for TDM was set at
€65, being the average national tariff for chromatographic complex
bioanalysis.
Costs of possible adverse events are based on an article by
Mickisch et al18 where costs per event of a variety of grade 3 and 4
adverse events are reported, for the UK, Germany, Italy and France.
By a lack of Dutch data, the adverse events costs of Germany are used
in this model, as the Dutch healthcare is most comparable with that of
Germany. and there are no Dutch data.
2.3.4 | Utilities
Utility weights used in this model were European Quality of Life
5‐Item Questionnaire (EQ‐5D) scores. The utility score for imatinib
was based on clinical trial data from Wilson et al19 and Chabot
et al20 for regular dose and escalated dose, respectively. Sunitinib util-
ity score was based on an article by Paz‐Ares et al21 which gathered
EQ‐5D scores of a phase III clinical study comparing GIST‐patients
treated with sunitinib and a placebo. Regorafenib utility scores were
based on EQ‐5D scores determined by the GRID study,5,22 a phase
III trial reporting on the efficacy and safety of regorafenib as treatment
for advanced GIST.
2.3.5 | Analyses
A probabilistic comparison of fixed dosing vs the TDM‐guided dosing
in the first line of treatment of GIST patients was performed from a
Dutch health‐care perspective. Additionally, sensitivity analyses were
conducted in order to explore overall parameter uncertainty. Analyses
were run using 5000 iterations, each stochastically sampling parame-
ter values in the determined ranges. Beta‐ and γ‐distributions
were used for transition probabilities and costs, respectively, and
plausible uncertainty was taken into account for all parameter range
distributions. Results of analyses were used to estimate incremental
cost‐utility ratios (ICUR). Additionally, scatter‐plots and cost‐
effectiveness acceptability curves were created to graphically describe
cost‐effectiveness.
2.3.6 | Sensitivity analyses
Currently, imatinib is patented by Novartis under the name
Glivec/Gleevec. This patent is set to expire in the near future,
resulting in drastic changes in the pricing of this drug. Decreased
generic drug costs or discounts up to 99% are possible. To determine
the effect of changes in drug pricing of imatinib on the cost‐
effectiveness of TDM, decreased drug costs of 50%, 80%, 95% and
99% were used. Other sensitivity analyses performed are variations
in imatinib and BSC utility values, as well as increased costs of adverse
events and BSC to determine whether or not the analyses are robust.
Discount rates of 4% and 1.5% were used for costs and QALYs,
respectively, in agreement of our national guidelines for pharmaco‐
economic research.23
3 | RESULTS
3.1 | Base case
Based on our model we estimated that over a 5‐year time horizon,
66% and 42% of the patients following the GIST treatment would
die in the fixed dosing and TDM group, respectively (Table 1). In the
fixed dosing group 14% of the patients would not progress beyond
the initial imatinib health‐state, compared with 35% in the TDM
health‐state. PFS in the TDM‐guided group was estimated to be
delayed compared with the fixed dosing group, and a lower amount
of deaths occurred in the TDM‐guided group. Subsequent treatment
lines showed similar progression and mortality rates relative to the
amount of patients entering these health‐states. Adverse events
occurred more frequently as patients progressed to the next lines of
treatment. BSC has the highest mortality rate for both fixed dosing
and TDM‐guided dose, with 96% and 95% of patients entering this
health‐state, respectively.
Average total costs over 5 years made were estimated to be
€106 994.85 (95% confidence interval [CI]: €104 468.90–
109 607.49) and €150 477.08 (95% CI: €145 862.62–155 475.62)
for fixed dosing and TDM‐guided dose, respectively. An average life‐
year gain of 0.78 (95% CI: 0.66–0.90) and a QALY gain of 0.74 (95%
CI: 0.61–0.88) were estimated with the use of TDM‐guided dosing
compared with fixed dosing (Table 2). Figure 2 shows the ICURs
observed over 5000 iterations of the model, with an average ICUR
of €58 785.70 (95% CI: €53 677.72–€66 750.60) per QALY. From
the cost‐effectiveness acceptability curve, one can read that the deci-
sion maker will be 100% sure that TDM‐guided dosing is favourable
over fixed dosing when society is willing to pay €72 000 or more
per QALY gained (Figure 3).
3.2 | Sensitivity analyses
The 1‐way sensitivity analyses for possible discounts, ranging from 50
to 99% discount, in imatinib drug prices showed a reduction in the
ICUR, yielding a cost of €21 993.54, €9094.02, €2627.29 and
€907.25 per QALY gained for 50%, 80%, 95% and 99% decreased
prizes, respectively (Figure 4).
Sensitivity analyses performed with variations in utility of the
health‐states, and costs of adverse events and BSC resulted in minor
changes in the ICUR. Only variations in the utility of the imatinib heath
state yielded relatively large changes in the ICUR. ICURs of
€76 321.64 and €54 464.70 were found when the health utility of
imatinib was decreased by 20%, and increased to perfect health,
respectively. A full overview of results of the sensitivity analyses is
presented in supplementary file 2.
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4 | DISCUSSION
We hypothesized that TDM would result in longer time to progression
and delayed costs related to second‐ and third‐line drugs. However,
TDM‐guided dosing was also expected to be more expensive due to
the laboratory costs made for TDM and higher doses of imatinib that
need to be given in subtherapeutic patients. The question was
whether the gain in health and related cost‐savings would outweigh
these extra costs.
Given the available data, these analyses suggest that the use of
TDM provides additional clinical benefit and may be cost‐effective for
patients with metastatic/unresectable GIST starting with imatinib as a
first line of treatment. An average ICUR of €58 758.70 per QALY
gained was found. The use of TDM is shown to be cost‐effective in
100% of the cases when a willingness to pay of €72 000.00 per QALY
gained is used. As a reference, in the Netherlands, a maximum cost
of €80 000 per QALY gained is widely used as the threshold value for
cost‐effectiveness in patients with highest burden of disease.24 Using
this metric, TDM can be regarded as a cost‐effective intervention for
use in the Netherlands, however this may not be the case for other
countries with different cost‐effectiveness thresholds. Ultimately, it is
up to the decision‐maker to decide whether ICURs are acceptable.
TABLE 1 Health‐state transitions for therapeutic drug monitoring (TDM)‐guided dosing and fixed dosing
Fixed dosing TDM
Health state n % n %
Imatinib Cohort 10 000 100 10 000 100
Not progressed 1424 14 3453 35
Progressed total 8576 86 6547 65
• progressed alive 4562 46 4580 46
• progressed dead 4014 40 1967 20
Adverse events 731 7 949 9
Imatinib escalated Cohort 4562 100 4580 100
Not progressed 1535 34 1895 41
Progressed total 3027 66 2685 59
• progressed alive 1473 32 1318 29
• progressed dead 1554 34 1367 30
Adverse events 1322 29 1188 26
Sunitinib Cohort 1473 100 1318 100
Not progressed 136 9 170 13
Progressed total 1337 91 1148 87
• progressed alive 948 64 816 62
• progressed dead 389 26 332 25
Adverse events 163 17 141 11
Regorafenib Cohort 948 100 816 100
Not progressed 204 22 197 24
Progressed total 744 78 618 76
• progressed alive 504 53 425 52
• progressed dead 240 25 194 24
Adverse events 431 46 354 43
Best supportive care Cohort 504 100 425 100
Alive 18 4 20 5
Dead 486 96 405 95
Total deaths 6683 67 4264 43
TABLE 2 Results base case analysis
Life years
(95% CI)
QALYs
(95% CI)
Cost, €
(95% CI)
Cost per life‐year,
€ (range)
Cost per QALY,
€ (range)
Fixed dosing 3.09
(2.97–3.21)
2.80
(2.58–2.99)
106 994.85
(104 468.90–109 607.49)
TDM‐guided dosing 3.87
(3.81–3.73)
3.54
(3.25–3.81)
150 477.08
(145 862.62–155 475.62)
Incremental 0.78
(0.66–0.90)
0.74
(0.61–0.88)
43 481.44
(36 107.33–50 636.58)
55 744.87
(53 173.74–58 657.33)
58 785.70
(53 677.72–66 750.60)
CI, confidence interval; QALY, quality‐adjusted life‐year.
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Our sensitivity analyses on potential decreased costs of imatinib in
the nearby future might support the uptake of our conclusion,
showing that ICUR will dramatically decrease with expected discounts
up to 99%. This can be explained by the fact that the imatinib drug
cost is the main cost‐driver in this analysis, due to the additional
imatinib doses given to patients to be treated within the therapeutic
index.
The additional sensitivity analyses showed no large effect on the
ICUR when parameters concerning the intermediary health‐states
were increased or decreased. Changes in parameters for health‐states
beyond the initial imatinib health‐state will affect both TDM‐guided
dosing and fixed dosing equally, showing minimal effect on the ICUR.
This shows that the results from our analyses are robust.
To our knowledge, this is the first cost‐effectiveness analyses
comparing the use of TDM‐guided dosing vs fixed dosing imatinib in
GIST patients. Moreover, no cost‐effectiveness analyses have been
performed on the effect of dose optimization based on TDM for oral
tyrosine kinase inhibitors so far. Therefore, our results are a valuable
addition to the existing knowledge.
TDM is set to be used in other sarcoma treatment drugs, such as
sunitinib and pazopanib, as well. While sunitinib is part of the line of
treatment used in this model, it was decided to not implement the
TDM of sunitinib in this model, due to an exponential increase in com-
plexity of the model. However, based on the results of this analysis, it
can be expected that the use of TDM in the sunitinib group as well as
the imatinib group may further increase the cost‐effectiveness, due to
additional prolonging of the time it takes to progress to regorafenib
and best supportive care.
One of the limitations in this study is that due to limited available
data, not all differences in the imatinib health‐state subgroups could
be taken into account. No clear consensus could be found whether
or not the occurrences of adverse events were significantly different
between these subgroups,9 resulting in the same occurrence of
adverse events being used among these subgroups. This may have
resulted in an underestimation of the effect of TDM in the imatinib
group, due to a lower occurrence of adverse events in the
supratherapeutic imatinib health‐state. Additionally, OS for the sub-
therapeutic imatinib group were not available, and have been
extrapolated based on the PFS of the imatinib subgroups, which may
result in either an over‐ or underestimation of the effect of TDM‐
guided dosing. Finally, the increase in PFS and OS induced by targeting
the predefined threshold is based on retrospective analyses of PK data
collected in several clinical studies while a prospective validation of this
target is currently still lacking. In patients with chronic myeloid
leukaemia, 1 small prospective study was conducted in only 55
patients in which no added value of routine TDM was demonstrated
mainly contributed to the nonadherence to dose‐adjustment advice
given.25
FIGURE 2 Incremental cost‐effectiveness ratio of fixed dosing vs
therapeutic drug monitoring‐guided dosing. Base case analysis run
with 5000 iterations
FIGURE 3 Cost‐effectiveness curve
comparing fixed dosing vs therapeutic drug
monitoring‐guided dosing
FIGURE 4 Effect of imatinib drug discounts on incremental cost
ratio
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This model makes a comparison based on an ideal situation, where
adherence from patients to all parts of the treatment is 100%. In
reality, this may not the case.26,27 This may have resulted in an
overestimation of the cost‐effectiveness of TDM‐guided dosing. The
effect of GIST and its treatment on absence from work and associated
costs were explored but ultimately not taken into account in this
model due to lack of available data. Due to prolonged time to progres-
sion, a larger number of patients may be able to participate in the
workforce, decreasing costs associated by absence from work, and
further increasing the cost‐effectiveness of TDM‐guided dosing vs
fixed dosing.
5 | CONCLUSION
This analysis suggests that TDM‐guided dosing provides additional
clinical benefit and may be cost‐effective compared to fixed dosing
in patients suffering from metastatic/unresectable GIST, using
imatinib as a first line of treatment, especially when imatinib loses its
patent whereby drugs costs will significantly decrease.
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